Shafique Virani - Jan 16, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Business Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Jan 16, 2024
Transactions value $
-$156,780
Form type
4
Date filed
1/18/2024, 06:39 PM
Previous filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $40K +18K +13.16% $2.22* 155K Jan 16, 2024 Direct F1
transaction RXRX Class A Common Stock Sale -$197K -18K -11.63% $10.93 137K Jan 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -18K -4.74% $0.00 361K Jan 16, 2024 Class A Common Stock 18K $2.22 Direct F1, F3
holding RXRX Stock Option (Right to Buy) 213K Jan 16, 2024 Class A Common Stock 0 $8.55 Direct F2
holding RXRX Stock Option (Right to Buy) 80.5K Jan 16, 2024 Class A Common Stock 0 $11.40 Direct F4
holding RXRX Stock Option (Right to Buy) 5.44K Jan 16, 2024 Class A Common Stock 0 $11.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023.
F2 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F3 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.